These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3969838)

  • 1. Relationship between CSF noradrenaline levels, C-EEG indicators of activation and psychosis ratings in drug-free schizophrenic patients.
    Kemali D; Maj M; Iorio G; Marciano F; Nolfe G; Galderisi S; Salvati A
    Acta Psychiatr Scand; 1985 Jan; 71(1):19-24. PubMed ID: 3969838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with increased noradrenaline levels in schizophrenic patients.
    Kemali D; Maj M; Galderisi S; Grazia Ariano M; Starace F
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):49-59. PubMed ID: 2300679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of indices of central dopaminergic functions in man.
    Bagdy G; Arató M; Baraczka K; Fekete MI
    Life Sci; 1983 Jun; 32(23):2667-76. PubMed ID: 6855463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF noradrenaline and schizophrenia.
    Kemali D; Maj M
    Am J Psychiatry; 1986 Jan; 143(1):126-7. PubMed ID: 3942277
    [No Abstract]   [Full Text] [Related]  

  • 5. Kinetic constants of platelet monoamine oxidase in schizophrenia.
    Jackman HL; Meltzer HY
    Am J Psychiatry; 1983 Aug; 140(8):1044-7. PubMed ID: 6869590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pimozide on CSF norepinephrine in schizophrenia.
    Sternberg DE; van Kammen DP; Lake CR; Ballenger JC; Marder SR; Bunney WE
    Am J Psychiatry; 1981 Aug; 138(8):1045-50. PubMed ID: 7258379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noradrenaline levels in cerebrospinal fluid of drug-free and pimozide-treated schizophrenic patients.
    Maj M; Arena F; Volpe M; Kemali D
    Acta Neurol (Napoli); 1983 Dec; 5(6):461-7. PubMed ID: 6670602
    [No Abstract]   [Full Text] [Related]  

  • 8. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
    van Kammen DP; Peters J; Yao J; van Kammen WB; Neylan T; Shaw D; Linnoila M
    Arch Gen Psychiatry; 1990 Feb; 47(2):161-8. PubMed ID: 1689140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid hydroxylase cofactor in schizophrenia.
    Garbutt JC; van Kammen DP; Levine RA; Sternberg DE; Murphy DL; Ballenger J; Bunney WE; Lovenberg WM
    Psychiatry Res; 1982 Apr; 6(2):145-51. PubMed ID: 6953456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased noradrenaline levels in CSF and plasma of schizophrenic patients.
    Kemali D; Del Vecchio M; Maj M
    Biol Psychiatry; 1982 Jun; 17(6):711-7. PubMed ID: 7104421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma norepinephrine in chronic schizophrenia.
    Breier A; Wolkowitz OM; Roy A; Potter WZ; Pickar D
    Am J Psychiatry; 1990 Nov; 147(11):1467-70. PubMed ID: 2221157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontal midline theta activity and platelet MAO in human subjects.
    Hashimoto M; Mukasa H; Yamada S; Nakamura J; Inanaga K
    Biol Psychiatry; 1988 Jan; 23(1):31-43. PubMed ID: 3337853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
    Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ
    Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet monoamine oxidase activity in schizophrenic patients.
    Becker RE; Shaskan EG
    Am J Psychiatry; 1977 May; 134(5):512-7. PubMed ID: 848577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of catecholamine metabolism in schizophrenia/psychosis--I.
    Maas JW; Contreras SA; Miller AL; Berman N; Bowden CL; Javors MA; Seleshi E; Weintraub S
    Neuropsychopharmacology; 1993 Feb; 8(2):97-109. PubMed ID: 8471132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients.
    Gattaz WF; Riederer P; Reynolds GP; Gattaz D; Beckmann H
    Psychiatry Res; 1983 Apr; 8(4):243-50. PubMed ID: 6576391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF 5-HIAA, attempted suicide and suicide risk in schizophrenia spectrum psychosis.
    Carlborg A; Jokinen J; Nordström AL; Jönsson EG; Nordström P
    Schizophr Res; 2009 Jul; 112(1-3):80-5. PubMed ID: 19410429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative EEG in never-treated schizophrenic patients.
    Omori M; Koshino Y; Murata T; Murata I; Nishio M; Sakamoto K; Horie T; Isaki K
    Biol Psychiatry; 1995 Sep; 38(5):305-9. PubMed ID: 7495924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients.
    Linnoila M; Ninan PT; Scheinin M; Waters RN; Chang WH; Bartko J; van Kammen DP
    Arch Gen Psychiatry; 1983 Dec; 40(12):1290-4. PubMed ID: 6197036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet MAO activity and long-term outcome in schizophrenia and schizoaffective disorder.
    Malas KL; van Kammen DP
    Am J Psychiatry; 1983 Jun; 140(6):794-6. PubMed ID: 6846644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.